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The societal burden of Alzheimer’s disease (AD) is staggering, with current estimates
suggesting that 50 million people world-wide have AD. Identification of new therapeutic
targets is a critical barrier to the development of disease-modifying therapies. A large
body of data implicates vascular pathology and cardiovascular risk factors in the
development of AD, indicating that there are likely shared pathological mediators.
Inflammation plays a role in both cardiovascular disease and AD, and recent evidence
has implicated elements of the coagulation system in the regulation of inflammation.
In particular, the multifunctional serine protease thrombin has been found to act as
a mediator of vascular dysfunction and inflammation in both the periphery and the
central nervous system. In the periphery, thrombin contributes to the development of
cardiovascular disease, including atherosclerosis and diabetes, by inducing endothelial
dysfunction and related inflammation. In the brain, thrombin has been found to act
on endothelial cells of the blood brain barrier, microglia, astrocytes, and neurons in
a manner that promotes vascular dysfunction, inflammation, and neurodegeneration.
Thrombin is elevated in the AD brain, and thrombin signaling has been linked to
both tau and amyloid beta, pathological hallmarks of the disease. In AD mouse
models, inhibiting thrombin preserves cognition and endothelial function and reduces
neuroinflammation. Evidence linking atrial fibrillation with AD and dementia indicates
that anticoagulant therapy may reduce the risk of dementia, with targeting thrombin
shown to be particularly effective. It is time for “outside-the-box” thinking about how
vascular risk factors, such as atherosclerosis and diabetes, as well as the coagulation
and inflammatory pathways interact to promote increased AD risk. In this review, we
present evidence that thrombin is a convergence point for AD risk factors and as such
that thrombin-based therapeutics could target multiple points of AD pathology, including
neurodegeneration, vascular activation, and neuroinflammation. The urgent need for
disease-modifying drugs in AD demands new thinking about disease pathogenesis and
an exploration of novel drug targets, we propose that thrombin inhibition is an innovative
tactic in the therapeutic battle against this devastating disease.
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INTRODUCTION
The societal burden of Alzheimer’s disease (AD) is staggering,
with current estimates suggesting that 5.8 million Americans
and 50 million people world-wide have AD (Alzheimer’s
Association, 2019). Identification of new therapeutic targets
is a critical barrier to our ability to develop a disease-
modifying therapy for this devastating disease. A large body
of data implicates vascular pathology and cardiovascular risk
factors, such as atherosclerosis and diabetes, in the development
of AD. Though the mechanisms whereby these risk factors
contribute to pathological processes in the AD brain have not
been defined fully, it has been suggested that inflammation
plays a key role in both cardiovascular disease and AD
(Grammas, 2011). It is clear that a better understanding of the
relationship(s) among cardiovascular risk factors, inflammation,
and neurodegeneration has the potential to reveal novel
therapeutic targets in the battle against AD.
Recently, a number of laboratories have provided evidence
that certain elements of the coagulation cascade may initiate
and/or support inflammation in the brain (Davalos and
Akassoglou, 2012; De Luca et al., 2017; Göbel et al., 2018).
The proinflammatory properties of the protein fibrin have
attracted particular attention [reviewed in Cortes-Canteli et al.
(2012), Petersen et al. (2018)]. Fibrin increases expression of
a number of inflammatory and oxidative mediators, activates
glial cells, and disrupts the blood-brain barrier (BBB). Another
potentially important protein related to both coagulation and
inflammation is thrombin. Thrombin is widely appreciated for
its contribution to fibrin formation and platelet aggregation
in response to vascular injury. Importantly, thrombin is also
a pleiotropic enzyme that is capable of triggering a large and
diverse number of cellular events through receptor-mediated
activation of protease-activated receptors (PARs) (Coughlin,
2005). Levels of both thrombin and the thrombin receptor PAR-
1 are elevated in AD (Sokolova and Reiser, 2008; Krenzlin
et al., 2016) and thrombin expression is increased in brain
microvessels collected from AD patients (Grammas et al.,
2006). As we discuss below, thrombin can act in both a
paracrine and autocrine manner to stimulate a noxious feed-
forward cycle that likely contributes to neuroinflammation in
the AD brain. The evidence summarized herein suggests that
thrombin is a convergence point for AD risk factors and that
thrombin-based therapeutics might target multiple points of AD
pathology, including neurodegeneration, vascular activation, and
neuroinflammation. We will present evidence that supports the




Close integration and extensive crosstalk between coagulation
and inflammation pathways are critical to the body’s response
to injury (Levi and van der Poll, 2005; Esmon, 2008).
Both processes utilize numerous bioactive mediators and
cellular effectors that interact in a coordinated manner.
Inflammatory proteins, such as cytokines, play a central
role in the activation of coagulation (Levi and van der Poll,
2005). Meanwhile major coagulation factors, such as tissue
factor, fibrinogen, and thrombin, are drivers of inflammation
(Jennewein et al., 2011; Davalos and Akassoglou, 2012; Kalz
et al., 2014; Witkowski et al., 2016; De Luca et al., 2017).
Under normal physiological conditions these intertwined
systems work in homeostatic balance, but dysregulation
of this crosstalk likely contributes to cellular injury and
disease pathogenesis.
Effect of Cytokines on Coagulation
Cytokines, particularly interleukin (IL)-6, tumor necrosis
factor-α (TNF-α), and IL-1β, stimulate procoagulant effects
both directly and indirectly. These proteins initiate the
extrinsic coagulation pathway through up-regulation and
activation of tissue factor (Nawroth and Stern, 1986;
Witkowski et al., 2016). Blocking tissue factor greatly
inhibits inflammation-induced thrombosis, and inhibition
of IL-6 specifically blocks tissue factor-dependent thrombin
generation (Levi et al., 1997). Cytokines, especially
TNF-α, can also initiate inflammation-mediated platelet
activation and clumping in the blood (Page et al., 2018).
Inflammatory cytokines can inhibit the anticoagulant
feedback pathways, resulting in increased thrombin and
fibrin production (Levi and van der Poll, 2005). Both
TNF-α and IL-1β can reduce activated protein C (APC) via
down-regulation of thrombomodulin, an important cofactor
for APC’s anti-inflammatory and anti-coagulant activity
(Nawroth and Stern, 1986).
Coagulation Factors Drive Inflammation
Tissue factor, the main driver of the extrinsic coagulation
pathway, can induce proinflammatory effects. This includes
increases in the production of inflammatory cytokines, adhesion
molecules, chemokines, and growth factors (Witkowski et al.,
2016). These proinflammatory effects are largely mediated
through tissue factor-activation of the protease thrombin (see
below). Fibrin is the primary end-product of the coagulation
system, but it also has proinflammatory characteristics.
Fibrinogen and fibrin both have been shown to induce
leukocyte migration, and directly modulate the inflammatory
response of both leukocytes and endothelial cells. Fibrin
induces the expression of several inflammatory cytokines
and chemokines and increases the production of reactive
oxygen species (ROS) (Jennewein et al., 2011). Similarly,
fibrin has been shown to have extensive proinflammatory
effects within the central nervous system (CNS), including
activation of glia and disruption of BBB function (Petersen
et al., 2018). Fibrinogen activates microglia in a CD11b-
dependent manner; this activation is related to perivascular
clustering, axonal degeneration, spine elimination, and cognitive
impairment in animal models (Davalos et al., 2012; Merlini
et al., 2019). Finally, the coagulation and immune systems
are directly linked through activation of IL-1α by thrombin
(Burzynski et al., 2019).
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The coagulation cascade consists of the intrinsic and extrinsic
pathways, and thrombin is a key mediator in both (Palta et al.,
2014). The extrinsic system is activated by tissue factor, which
is found in the subendothelial surface and is only introduced to
the blood following injury. Tissue factor in the blood complexes
with factor VIIIa to initiate the cascade that will eventually lead
to the formation of thrombin and the cleavage of fibrinogen to
fibrin (Witkowski et al., 2016). The intrinsic system is activated
by factor XII, which initiates a cascade that will lead to the
production of thrombin via factors X and V (Palta et al., 2014).
The activation of thrombin will also activate a positive feedback
loop which will continue to drive the generation of thrombin
(Palta et al., 2014). Together, these systems work to increase
the amount of active thrombin in the blood, which will in
turn increase the insoluble fibrin available to form a clot at
the site of damage.
As noted above, thrombin is a multifunctional protease
that can initiate many cellular events through action at and
activation of PARs. PARs are a unique class of G-protein-coupled
receptors due to their unusual tethered-ligand mechanism
of activation (Coughlin, 2000). Thrombin is responsible for
enzymatic cleavage of the PAR N-terminus to expose a tethered
ligand that intramolecularly activates the receptor. Activation of
PARs by thrombin affects a multitude of functions throughout the
body, including the regulation of platelet activation, cell adhesion,
cell migration, angiogenesis, and inflammation (Coughlin, 2005;
Kalz et al., 2014).
The Vasculature Is a Critical Nexus for
the Proinflammatory Actions of
Thrombin
Thrombin moderates gene expression through a wide array
signaling processes in vascular endothelial cells (Cheranova
et al., 2013) and much of thrombin’s proinflammatory activity
is likely due to its numerous effects on vascular endothelial
cells. Thrombin acts on endothelial cells to stimulate synthesis
and release of a large number of diverse bioactive proteins.
Thrombin stimulation of human umbilical vein endothelial
cells (HUVECs) produces changes in gene expression related
to inflammation, apoptosis, and matrix integrity (Okada
et al., 2006). Thrombin-treated HUVECs exhibit increased
expression of intracellular adhesion molecule-1 (ICAM-1) and
vascular cell adhesion molecule-1 (VCAM-1) and a related
increase in monocyte adhesion (Kaplanski et al., 1998). In
human aortic endothelial cells (HAECs), thrombin and high-
glucose co-treatment produces increases in the expression
of NADPH oxidase (NOX), inflammatory cytokines, and
altered adhesion (Wang et al., 2014). Cultured endothelial
cells exposed to thrombin release von Willebrand factor,
express P-selectin at the plasma membrane, and produce
chemokines thought to trigger the binding of platelets
and leukocytes to endothelial surface (Collins et al., 1993).
Thrombin can affect vessel diameter, alter endothelial cell
shape, and increase permeability of the endothelial monolayer.
Endothelial cells can both release thrombin and respond
to this protein via functionally active thrombin receptors
(PAR-1 and PAR-3). Thrombin causes endothelial activation and
enhanced expression and/or release of many proinflammatory
proteins including monocyte chemoattractant protein-1
(MCP-1), ICAM-1, IL-1, IL-6, and IL-8, which in turn
can injure endothelial cells leading to increased release of
thrombin (Colotta et al., 1994; Marin et al., 2001; Rahman
et al., 2002; Miho et al., 2005; Okada et al., 2006; Yin et al.,
2010; Ishibashi et al., 2014). Thus, thrombin can act in both
a paracrine and autocrine manner stimulating a noxious
feed-forward cycle.
THROMBIN CONTRIBUTES TO THE
DEVELOPMENT OF ALZHEIMER’S RISK
FACTORS: ATHEROSCLEROSIS AND
DIABETES
Given thrombin’s effect on endothelial cells, it is not surprising
that thrombin has been implicated in the pathogenesis of
atherosclerosis. Thrombin has been widely studied for its role
in the pathology of atherosclerosis, a progressive and chronic
inflammatory vascular disorder (Kalz et al., 2014; Jaberi et al.,
2019). A role for thrombin in the development of atherosclerosis
is suggested by the observation that elevated levels of thrombin
and the thrombin receptor PAR are found around atherosclerotic
plaques, and that thrombin formation is correlated with disease
severity in coronary atherosclerosis (Borissoff et al., 2012).
Thrombin facilitates recruitment of circulating monocytes to
atherosclerosis plaques by increasing expression of MCP-1,
ICAM-1, and VCAM-1 (Colotta et al., 1994; Minami et al.,
2004; Kalz et al., 2014). The importance of thrombin is
further highlighted by the finding that thrombomodulin, which
inhibits thrombin by binding to it, diminishes thrombin-induced
endothelial cell dysfunction in atherosclerosis (Wei et al.,
2011). Thrombin produces damage to endothelial cell barriers
causing leakiness and associated leukocyte migration (Kalz et al.,
2014). Thrombin inhibition has been shown to decrease ROS
production, improve endothelial cell and barrier function, and
attenuate atherosclerotic plaque formation (Lee et al., 2012).
Thrombin activity can influence onset, progression,
and qualitative properties of atherosclerotic plaques. In
atherosclerotic models, increases in thrombin have been found
to be associated with increases in inflammation, angiogenesis,
and cell proliferation (ten Cate, 2012; Kalz et al., 2014).
Genetic reduction of thrombin in APOE-/- mice diminished
atherosclerosis severity (Borissoff et al., 2013). Studies have
further defined thrombin’s role in atherosclerosis by finding
reduced atherosclerosis-related pathology in animal models
treated with thrombin inhibitors (Wei et al., 2011; Pingel et al.,
2014; Preusch et al., 2015; Palekar et al., 2016). On the other
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hand, genetic manipulations resulting in elevated thrombin
levels produce exacerbated atherosclerosis-related pathology
(Borissoff et al., 2013). These findings illustrate a causative role
for thrombin in the development of atherosclerosis-related
pathology and inflammation, largely through thrombin’s
endothelial cell-mediated effects.
Hyperglycemia, characteristic of Type 2 diabetes mellitus
(T2DM), enhances thrombin generation and promotes a
hypercoagulable state and high oxidative stress (Aoki et al.,
1996; Undas et al., 2008; Chapman, 2013). Elevated thrombin
activity has been linked with endothelial dysfunction in
diabetes, including vascular inflammation and increased
ROS production in Paneni et al. (2013). One mechanism
whereby thrombin promotes diabetic oxidative stress is via
calcium-mediated intracellular signaling pathways that regulate
the transcription factor KLF14 and PLK1 kinase pathways,
resulting in increased ROS production (Hao et al., 2018).
Exogenous thrombin treatment has been shown to exacerbate
pathology in experimental models of diabetes. In a mouse
model of diabetes, thrombin treatment of pericytes results in
increased barrier permeability, decreased expression of tight
junction proteins, and increased expression of inflammatory
cytokines (Machida et al., 2017). Induction of diabetes by
streptozotocin (STZ) in mice increases the expression of
PAR-1, PAR-3, and PAR-4 in the aorta. STZ-induced diabetic
mice show impairment of endothelial function, while the
administration of dabigatran etexilate, a direct thrombin
inhibitor, significantly attenuates this endothelial dysfunction
(Rahadian et al., 2020).
Patients with T2DM show increased blood thrombin
levels correlated with the patient’s level of albuminuria,
an indicator of cardiovascular morbidity and mortality in
patients with T2DM. This suggests that thrombin may play
a role in the development of macrovascular disease (Ay
et al., 2012). Thrombin-related pathways have also been
implicated in diabetic microvascular injury and retinopathy.
Samples taken from diabetic retinopathy patients show elevated
expression of thrombin and PAR-1; similar trends are found
in samples from a rat model of diabetes (Abu El-Asrar
et al., 2016). Obesity promotes a chronic inflammatory and
hypercoagulable state that drives cardiovascular disease
and T2DM. Recent studies have suggested a link between
the thrombin/fibrin (ogen) axis and obesity (Kopec et al.,
2017). In a high fat animal model, treatment with the
direct thrombin inhibitor dabigatran etexilate ameliorates
the development of obesity and severity of associated sequelae
(Kopec et al., 2014).
THROMBIN CAUSES VASCULAR
DYSFUNCTION AND PROMOTES
INFLAMMATION IN THE BRAIN
Largely due to its proinflammatory effects on endothelial
cells, thrombin has an important role in the pathology of
various peripheral vascular diseases, including atherosclerosis
and diabetes, as reviewed above. Thrombin may similarly act
FIGURE 1 | Thrombin-induced endothelial cell activation: a link between
CVRFs and AD. The Venn diagram illustrates a proposed role for
thrombin-mediated endothelial cell (EC) injury as a common link between
cardiovascular disease and AD. Thrombin’s proinflammatory effects on ECs in
the periphery, characterized by increased reactive oxygen species, cytokines
and chemokines, barrier permeability and leukocyte adhesion, contribute to
the pathogenesis of cardiovascular disease. Similarly, thrombin may contribute
to the development of AD by causing EC activation in the cerebral
microcirculation.
as a pathological mediator in the CNS, through effects on the
endothelial cells of the BBB (Figure 1).
Effects of Thrombin on the BBB
Consistent with its ability to cause endothelial injury in the
periphery, thrombin has been found to be involved in instances
of damage and dysfunction to the brain endothelial cells of the
BBB. Treatment of rat brain endothelial cells causes endothelial
dysfunction characterized by increased production of ROS,
nitric oxide (NO), inflammatory cytokines, and chemokines
(Brailoiu et al., 2017). In human brain endothelial cells, thrombin
treatment induces an inflammatory phenotype resulting in
increased ICAM-1, VCAM-1, and increased mRNA expression
for CXC chemokines (chemotactic for neutrophils) CXCL1
(GRO-alpha), CXCL2 (GRO-beta) CXCL8 (IL-8), and CXCL10
(IP-10) (Alabanza and Bynoe, 2012). Thrombin also increases
F-actin stress fibers, disrupts tight junctions, and increases
barrier permeability (Brailoiu et al., 2017). More specifically,
thrombin has been found to alter barrier permeability by
inducing microtubule disassembly (Birukova et al., 2004) and
activating Src kinase (Liu et al., 2010). Treatment with a direct
thrombin inhibitor reduces the ROS generation and expression
of proinflammatory cytokines by cultured brain endothelial
cells in response to hypoxia, indicating a mediating role for
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FIGURE 2 | Hypothetical scheme for thrombin as a mediator of
cerebrovascular activation, neuroinflammation, and neurodegeneration.
A hypothetical scheme for thrombin as a mediator of cerebrovascular
activation, neuroinflammation, and neurodegeneration. Thrombin can cause
neuronal injury directly and indirectly by activation of endothelial cells (ECs)
and glia. Thrombin can act on ECs of the blood-brain barrier (BBB) to cause
endothelial activation characterized by increased permeability and an increase
in reactive oxygen species (ROS), nitric oxide (NO), and inflammatory proteins
including thrombin. These toxic vascular-derived products can injure neurons
as well as activate neighboring glial cells to release noxious mediators which in
turn cause neuronal injury.
thrombin in the proinflammatory response of brain endothelial
cells (Tripathy et al., 2013).
We have previously demonstrated that thrombin message
is highly expressed in microvessels from AD brains but is
not detectable in control vessels (Yin et al., 2010). Similarly,
Western blot analysis of microvessels shows that the thrombin
protein is highly expressed in AD- but not control-derived
microvessels (Grammas et al., 2006). Furthermore, injuring
brain endothelial cells in vitro with oxidant stress (sodium
nitroprusside) or an inflammatory cocktail (IL-1β, IL-6, TNF-α,
lipopolysaccharide (LPS), interferon (IFN)-γ) results in thrombin
release (Grammas et al., 2004). Since brain endothelial cells can
both synthesize and respond to thrombin, it could function as an
autocrine factor at the BBB. The importance of findings regarding
the effects of thrombin on the cells of the BBB is two-fold.
Directly, thrombin damage to the BBB increases permeability
and may allow damaging substances, including thrombin and
other inflammatory mediators from the blood, to enter the brain.
Indirectly, these injured brain endothelial cells can produce their
own thrombin into the brain, where it may have untoward effects
on microglia, astrocytes and neurons (Figure 2).
Neuroinflammatory Effects of Thrombin
on Microglia and Astrocytes
The response of microglia to thrombin encompasses a number
of processes that contribute to microglia activation and/or
apoptosis. In the microglial cell line BV2, thrombin induces
IL-1β release (Han et al., 2019). Thrombin has also been
shown to stimulate a proinflammatory phenotype in microglia,
characterized by increases in ROS, NO, and cytokine production
(Lee et al., 2006; Huang et al., 2008; Yang et al., 2015;
Ye et al., 2017). PAR-1 activation was found to participate in
activation of microglia, indicated by up-regulation of microglial
CD40 and TNF-α production (Suo et al., 2002). Thrombin, via
the TNF-α/TNFR-dependent pathway, downregulates expression
of the mRNA species miR-181c which in turn promotes nuclear
factor (NF)-κB activity, and upregulates NF-κB target gene
expression as well as increasing mixed lineage leukemia-1
(MLL1), a putative gene target for miR-181c (Yin et al., 2017).
BV2 cells treated with thrombin show an increase in ROS
and the nucleotide-binding domain, leucine-rich-containing
family, pyrin domain-containing-3 (NLRP3) inflammasome, a
component of the innate immune system, which is associated
with a wide range of human CNS disorders (Ye et al., 2017).
Astrocytes show a similar shift towards a proinflammatory
phenotype in response to thrombin. In rat brain astrocytes,
thrombin induces matrix metalloproteinase (MMP)-9
expression and promotes cell migration via activation of
the c-Src/Jak2/PDGFR/PI3K/Akt/PKCδ pathway (Lin et al.,
2013). Thrombin exposure can disrupt glutamate transport in
astrocytes and modulate stellation, indicating an alteration in
function (Cavanaugh et al., 1990; Piao et al., 2015). Thrombin
treatment in vivo resulted in increased glial fibrillary acidic
protein (GFAP) expression in the hippocampus, indicating a
proinflammatory activation in astrocytes (Mhatre et al., 2004).
THROMBIN: AN IMPORTANT MEDIATOR
OF NEUROTOXICITY AND
NEURODEGENERATIVE DISEASES
The multifunctional protease thrombin causes neuronal
cell death both in vitro and in vivo, and the neurotoxic
effects of thrombin are orchestrated by multiple pathways.
In vitro, thrombin-induced neurotoxicity involves activation
of PAR-1, followed by RhoA activation and cell cycle re-
entry. In neurons treated with thrombin, cyclin D1 and E
(early G1 cyclins) and the cyclin dependent kinase, cdk4,
are activated and that these events lead to upregulation of
the pro-apoptotic protein Bim and apoptosis (Rao et al.,
2007). Additionally, thrombin has been demonstrated to
cause a rapid influx of calcium in neurons leading to
neuronal cell death (Smirnova et al., 1998). Delivery of
thrombin directly into the brain by intracerebral injection
causes significant neuropathology, such as enlargement of
cerebral ventricles, an increased number of TUNEL-positive
cells, astrogliosis, and an increase in the immunoreactivity
for phosphorylated neurofilament and apolipoprotein-E
(ApoE) fragments, as well as cognitive impairments including
deficits in reference memory and an increase in task latency
(Mhatre et al., 2004). The large body of data indicating
thrombin is an important mediator of neuroinflammation and
neurotoxicity support the idea that this protein is critically
involved in pathological processes that contribute to the
development of neurodegenerative diseases including multiple
sclerosis (MS), amyolaterotrophic sclerosis (ALS), ischemia,
traumatic brain injury (TBI), Parkinson’s disease (PD), and AD
(Krenzlin et al., 2016).
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Alterations in coagulation-related proteins have been
indicated in motor-associated degenerative disorders. Both
prothrombin and factor X are elevated in MS (Gobel et al., 2016).
Proteomic analysis of chronic active MS lesions identified several
dysregulated coagulation factors, highlighting a potential link
between the coagulation cascade and MS pathology (Han et al.,
2008). In experimental autoimmune encephalomyelitis (EAE),
an experimental model of MS, thrombin activity precedes onset
of neurological signs, increases at disease peak, and correlates
with fibrin deposition, microglial activation, demyelination,
axonal damage, and clinical severity (Davalos et al., 2014).
The potential pathological significance of coagulation factors
in neurological disease is underscored by the finding that the
diminution of fibrin, the end product of thrombin’s proteolysis,
either genetically or using anticoagulants, significantly reduces
neurological signs, inflammation, and axonal damage in EAE
(Davalos and Akassoglou, 2012). Additionally, thrombin has
been linked to changes in interneuron calcium signaling and
enhanced thrombospondin release in ALS (De Luca et al., 2017).
Thrombin has been extensively studied for its role in the
response to ischemia (Matsuoka and Hamada, 2002). Thrombin
was found to mediate neurovascular injury during ischemia
(Chen et al., 2010), and increased thrombin activity was
associated with subsequent neuronal damage in a model of acute
focal ischemia (Chen et al., 2012). While high concentrations of
thrombin seem to be neurotoxic, low concentrations of thrombin
(0.01 U/mL) were found to protect against neuronal death in
cellular and animal models of ischemia (Striggow et al., 2000).
Increases in thrombin have also been associated with TBI.
Alterations in BBB permeability have been found following TBI
(Korn et al., 2005; Hay et al., 2015). In a model of TBI, BBB
damage due to the injury was found to induce increases in
thrombin (Piao et al., 2019).
A role for thrombin has also been identified in PD-related
pathology. More specifically, thrombin-induced activation
of microglia in the midbrain has been directly linked to
dopaminergic neuron death (Choi et al., 2003). Thrombin
receptor PAR-1 is upregulated in the brains of patients with PD
(Ishida et al., 2006; Sokolova and Reiser, 2008). Recently, our lab
has identified that treatment with the direct thrombin inhibitor
dabigatran improved motor deficits and reduced markers of
oxidative stress in a Drosophila melanogaster model of PD
(Johnson et al., 2020). A role for thrombin in PD is further
indicated by the finding that treatment with a direct thrombin
inhibitor is neuroprotective in a rotenone-induced PD rodent
model (Kandil et al., 2018). Finally, mice deficient in PAR-1 are
protected against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP)-induced toxicity which causes PD-like syndrome
(Hamill et al., 2007).
A CASE FOR THROMBIN AS A DRIVER
OF NEURODEGENERATION AND
VASCULAR ACTIVATION IN AD
Thrombin has previously been suggested as a possible
pathological mediator in AD (Grammas and Martinez, 2014).
Thrombin is associated with typical hallmarks of AD-related
pathology. Thrombin has been detected in senile plaques and
in neurofibrillary tangles characteristic of this disease (Akiyama
et al., 1992; Arai et al., 2006) and levels of both thrombin and
the thrombin receptor PAR-1 are elevated in AD (Sokolova and
Reiser, 2008; Krenzlin et al., 2016). TBI, a condition in which
neurons are exposed to high thrombin levels, is associated with
an increased incidence of AD (Mortimer et al., 1991; Nemetz
et al., 1999). Thrombin may also contribute to ApoE-associated
pathology in AD. Intracerebral administration of thrombin to
rodents increases ApoE levels in the hippocampus and results
in neuronal injury and cognitive deficits (Mhatre et al., 2006).
The 22 kDa N-terminal thrombin-cleavage fragment of ApoE
is highly neurotoxic and could contribute to ApoE-associated
AD pathology (Tolar et al., 1997). Persistent thrombin signaling
induces tau aggregation and related hippocampal degeneration
(Suo et al., 2003; Arai et al., 2005). Thrombin induces secretion
of amyloid precursor protein (APP) in endothelial cells in vitro
(Ciallella et al., 1999) and may be involved in altered processing
of APP into fragments that are found in amyloid plaques of
AD brains (Igarashi et al., 1992; Chong et al., 1994; Ciallella
et al., 1999). Aβ promotes thrombin generation through factor
XII-mediated factor XI activation (Zamolodchikov et al., 2016).
In this regard, depletion of factor XII ameliorates brain pathology
and cognitive impairment in AD mice. Additionally, the factor
XII-initiated contact system, of which thrombin is a key driver, is
activated in AD patients and mice (Zamolodchikov et al., 2015;
Chen et al., 2017).
Vascular Activation: A Novel Pathway in
AD: A Role for Thrombin
Microvessels isolated from the brains of AD patients overexpress
a diverse array of neurotoxic and inflammatory proteins
(Grammas and Ovase, 2001; Grammas et al., 2006). Expression
of these diverse mediators is consistent with the process of
vascular activation and reflects the transition of endothelial
cells from a quiescent to a highly synthetic phenotype (Sumpio
et al., 2002). A similar pattern of vascular activation has been
identified in transgenic AD animal models (Grammas et al.,
2014). Vascular activation in the AD brain has deleterious
consequences for neuronal viability, as many vascular-derived
factors are neurotoxic. The idea that vascular activation
contributes to pathogenic events in the AD brain is strongly
supported by pre-clinical studies in two AD mouse models
where treatment with a vascular activation inhibitor reduced
vascular-derived neuroinflammation and improved cognitive
performance (Grammas et al., 2014).
Several lines of evidence support the idea that the cerebral
vasculature is a convergence point for both the expression of
thrombin as well as thrombin-mediated effects that contribute
to neuroinflammation and neuronal injury in AD. While the
majority of thrombin is produced in the liver, extrahepatic
sources of locally generated thrombin, including in the brain,
have been documented (Deschepper et al., 1991). Although not
widely appreciated, evidence suggests the cerebrovasculature is
an important source of thrombin in AD. Immunoreactivity
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for the major brain thrombin inhibitor, protease nexin-1, is
found to be significantly decreased in AD brains, particularly
around blood vessels, suggesting vascular release of thrombin
(Vaughan et al., 1994). As previously stated, thrombin mRNA
and protein are expressed in brain microvessels from AD
patients but not detectable in brain microvessels isolated from
age-matched control brains (Grammas et al., 2006; Yin et al.,
2010). It is not surprising that thrombin is expressed in AD-
derived brain microvessels, as in vitro experiments with brain
endothelial cells have shown that injuring these cells causes
release of thrombin (Grammas et al., 2004). Because brain
endothelial cells not only produce thrombin in response to
injury but respond to thrombin with a robust inflammatory
response, thrombin is likely a key mediator of cerebrovascular
activation in AD.
The release of vascular-derived inflammatory proteins
could stimulate/activate neighboring glial cells, both microglia
and astrocytes, to release inflammatory proteins as well as
noxious ROS and proteases (Grammas, 2011). This noxious,
neurotoxic cycle could be augmented by vascular-derived
thrombin. In addition to thrombin’s inflammatory effects on
brain endothelia, thrombin could contribute to deleterious
and self-perpetuating neuroinflammation via induction of
proinflammatory cytokines including IL-1β, IL-6, TNF-α in
microglia and astrocytes (Choi et al., 2003, 2008; Lee et al., 2006;
Huang et al., 2008). A recent study in the TgCRND8 AD mouse
showed that long-term treatment with the thrombin inhibitor
dabigatran preserved cognition, cerebral perfusion, and BBB
function, and ameliorated neuroinflammation and amyloid
deposition (Cortes-Canteli et al., 2019). Administration
of dabigatran to transgenic AD mice diminishes ROS
levels in brain and reduces cerebrovascular expression of
inflammatory proteins, further supporting an important role for
thrombin as a mediator of neuroinflammation in the AD brain




Increasing evidence supports a chronic procoagulant state
in AD, highlighting a possible pathogenic role for thrombin
in this disease (Cortes-Canteli et al., 2012). A number of
studies in both human populations and animal models
utilizing anticoagulant therapies support the notion that
abnormalities of coagulation may promote AD pathology.
Treatment of transgenic AD mice with enoxaparin, a
low molecular weight heparin, reduces plaques, and Aβ
accumulation (Bergamaschini et al., 2004) and improves
spatial memory (Timmer et al., 2010). As previously stated,
TgCRND8 AD mice on long-term dabigatran administration
also showed significant improvement in AD pathology
(Cortes-Canteli et al., 2019).
Earlier human studies showed improved cognition in
dementia patients receiving the anticoagulant warfarin compared
to untreated patients (Puccio et al., 2009). Results from these
older studies in human patients hinted at a connection between
dementia and coagulation abnormalities, but these data were
not rigorously pursued. A more recent community-based study
found that use of the thrombin inhibitor dabigatran was
associated with a lower risk of new-onset dementia (Jacobs
et al., 2016). An epidemiological study on atrial fibrillation
(AF) patients shows increased thrombin generation and fibrin
turnover in subjects with AF and dementia compared to
those without dementia, and that long-term warfarin treatment
appears to be protective against dementia (Barber et al., 2004;
Madhavan et al., 2018).
The evidence supporting a direct connection between
AF and dementia suggests the possibility that anticoagulant
therapy for AF may reduce the incidence of dementia in
this population, and results obtained in a number of recent
population-based studies suggest that this is indeed the case
(Ding et al., 2018; Field et al., 2019; Mongkhon et al., 2019;
Silva et al., 2019). Interestingly, while some groups have
found that all anticoagulants provide a level of protection
(Friberg and Rosenqvist, 2018) most studies report that the
direct oral anticoagulants (DOACs) that target thrombin are
particularly efficacious (Jacobs et al., 2016; Chen et al., 2018;
Cheng et al., 2018). It is tempting to conclude that DOACs
reduce the risk of AF-related dementia by decreasing the
incidence of thrombotic and/or embolic events, but this scenario
may be overly simplistic. While there is clear evidence that
AF is associated with an increased risk of ischemic stroke
(Glotzer and Zieglerm, 2015) an ambitious meta-analysis
of 21 studies found that the association between AF and
dementia was not always dependent on the presence of clinical
stroke (Kalantarian et al., 2013), raising questions regarding
the mechanisms underlying this association (Chopard et al.,
2018). Dietzel et al. (2018) have postulated that AF initiates
and perpetuates an increase in systemic inflammation that
may lead to dementia, noting recent evidence that AF is
associated with increased levels of C-reactive protein (CRP),
IL-2, IL-6, IL-8, TNF-α, and other inflammatory cytokines.
It is probable that thrombin is a key mediator of this
inflammatory state, as it is for the inflammation that accompanies
AD dementia. Furthermore, the utility of DOACs in the
reduction of AF-related dementia is at least partially due to
the ability of these agents to inhibit thrombin’s PAR-mediated
inflammatory actions.
It is therefore possible to interrupt the inflammatory cascade
that contributes to AD by utilizing DOACs to inhibit thrombin.
There is as yet no direct evidence that this approach will
be useful in humans, but an open-label study of a hirudin
(natural antithrombin anticoagulant) compound in 84 patients
with mild-to-moderate AD found that hirudin plus donepezil
reduced the rate of cognitive decline compared to donepezil
alone, suggesting that direct thrombin inhibition may indeed be
an effective strategy for treating this neurodegenerative disease
(Li et al., 2012).
Although the use of any anticoagulant raises the possibility
of unwanted bleeding, several studies have shown the safety and
efficacy of dabigatran. Dabigatran does not interact with food, has
minimal drug-drug interactions, and has a low risk of intracranial
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bleeding. A study documented chronic use (over 30 months) of
dabigatran in patients with an average age of 71.4 ± 8.6 had
minimal side effects, supporting the efficacy and safety of this
drug in an elderly population (Jacobs et al., 2016). Although
not without caveats, a body of data implicating thrombin in AD
pathogenesis and the relative safety of dabigatran suggest a pilot
clinical trial in AD patients is warranted.
CONCLUSION
The urgent need for disease-modifying drugs in AD demands
new thinking about disease pathogenesis and an exploration of
novel drug targets. A large, and growing, literature implicates
vascular pathology and vascular risk factors in the development
of AD, but the specific mechanisms whereby these factors
contribute to injury in the AD brain have not yet been clearly
defined. It is time for “outside-the-box” thinking about how
vascular risk factors, such as atherosclerosis and diabetes, as
well as the coagulation and inflammatory pathways interact to
promote increased AD risk. The evidence summarized here
suggests that thrombin is a convergence point for AD risk
factors and as such that thrombin-based therapeutics may
therefore target multiple points of AD pathology, including
neurodegeneration, vascular activation, and neuroinflammation.
Next generation AD therapeutics should not focus on single-
target drugs but rather employ a broader, combinatorial
approach. We propose that thrombin inhibitors be considered as
potential contributors to the dementia therapy pharmacopeia.
FUTURE DIRECTIONS
The use of dabigatran and other DOACs as a novel strategy for the
treatment of AD and possibly other neurodegenerative diseases
where thrombin plays a role is warranted. In addition, with
the increasing interest/use of newer tools, such as microRNAs,
other innovative therapeutic approaches that target thrombin
could be employed. MicroRNAs are short regulatory RNA
molecules that control gene expression at the posttranscriptional
level by affecting the translation and stability of mRNA targets
(Simonson and Das, 2015). Evidence suggests that microRNAs
are important regulators of neuronal survival, endothelial injury,
and inflammatory signaling (Suárez et al., 2007; Fish et al., 2008;
Harris et al., 2008; Wang et al., 2008; Wojciechowska et al., 2017;
Slota and Booth, 2019). Thrombin, which is at the nexus of all
three of these processes, could mediate its effects, in part, via
microRNAs. The literature in this area is evolving but studies
are beginning to identify thrombin-targeted microRNAs in the
development of vascular injury and neuroinflammation (Table 1;
Shen et al., 2011; Cowan et al., 2014; Kim et al., 2014; Mehi et al.,
2014; Pan et al., 2014; Wang et al., 2014; Lin et al., 2016; Li et al.,
2017; Yin et al., 2017; Barwari et al., 2018; Miao et al., 2018; Yao
et al., 2019; Cui et al., 2020).
There is increased recognition that effective therapies for AD
must shift from the classical “one-size-fits-all” approach to a
personalized precision medicine strategy (Hampel et al., 2017).









miR-181b ↓ CARD10 Endothelial cell
activation
Lin et al., 2016
miR-181c ↓ MLL1 Microglia activation Yin et al., 2017
miR-146 ↑ CARD10 Endothelial cell
activation
Cowan et al., 2014
miR-146a ↓ NOX4 Inflammation Wang et al., 2014
miR-10b ↑ HOXD10 Angiogenesis Shen et al., 2011
miR-let7c ↑ IGF-1R Intracerebral
hemorrhage
Kim et al., 2014
miR-27b ↓ TSP-1 Angiogenesis Miao et al., 2018
miR-21 ↑ WASp Inflammation,
Fibrosis
Li et al., 2017;
Barwari et al., 2018
miR-339 ↑ Klotho Inflammation Mehi et al., 2014; Li
et al., 2017
miR-223 ↑ IGF-1R Inflammation
Apoptosis






Cui et al., 2020
miR-25-3p ↑ ADAM10 Inflammation Yao et al., 2019
ADAM10, a disintegrin and metalloproteinase domain-containing protein 10;
CARD10, caspase recruitment domain-containing protein 10; HoxD10, homeobox
D10; IGF-1R, insulin-like growth factor type 1 receptor; MLL1, mixed lineage
leukemia protein-1; NOX4, NADPH oxidase 4; PHD1, prolyl hydroxylase domain
1; TSP-1, thrombospondin-1; WASp, Wiskott–Aldrich syndrome protein.
Inter-individual variability in response to pharmacotherapy as
well as molecular/physiologic “subtypes” of patients within the
broad category of AD support the rationale for a personalized
therapeutic approach based on unique genetic characteristics and
individual lifestyle attributes (Hahn and Lee, 2019). There is
growing interest in the use of pharmacogenomics to optimize the
safety and efficacy of DOACs in anticoagulation therapy (Tseng
et al., 2018). As more data using this approach become available,
incorporating DOACs into a personalized precision medicine
approach for the treatment of AD could be accomplished in
the near future.
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